MLH1 and neoplasm: Of these, 1%‐3% are due to LS while most of the remaining MMR‐deficient tumours have somatic inactivation of MLH1 via hypermethylation of the gene promoter.7 In MMR‐deficient tumours, both copies of the same MMR gene have been inactivated, resulting in no production of the respective protein product.